Abstract
Background: Tamoxifen is a selective oestrogen receptor modulator that is used in the treatment of hormone receptor positive breast cancer. It has been shown to significantly reduce the risk of breast cancer recurrence and has been shown to improve breast cancer survival. It is however associated with an increased risk of thromboembolic events, with an increased risk in patients undergoing free flap breast reconstruction due to the prolonged period of immobility. As tamoxifen has implications for macrovascular thrombosis, this study aimed to assess if it has implications for microvascular thrombosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
